Semaglutide vs Thymulin
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Semaglutide
Semaglutide is a GLP-1 receptor agonist that has revolutionized weight management and diabetes treatment. FDA-approved as Ozempic (diabetes), Wegovy (weight loss), and Rybelsus (oral form), it has become one of the most prescribed peptides worldwide.
Full details →Thymulin
Thymulin (Facteur Thymique Sérique) is a zinc-dependent nonapeptide hormone produced by thymic epithelial cells. It plays important roles in T-cell differentiation and immune system maturation.
Full details →Side-by-Side Comparison
| Aspect | Semaglutide | Thymulin |
|---|---|---|
| Mechanism | Mimics glucagon-like peptide-1 (GLP-1) to stimulate insulin secretion, suppress glucagon release, slow gastric emptying, and reduce appetite through hypothalamic signaling. The result is significant reduction in food intake and improved glycemic control. | Requires zinc for biological activity. Promotes T-cell differentiation, modulates cytokine production, and influences neuroendocrine function. Levels decline significantly with age. |
| Typical Dosage | Wegovy (weight loss): Start at 0.25mg weekly, titrate up to 2.4mg weekly over 16-20 weeks. Ozempic (diabetes): 0.25mg to 1mg weekly. Research protocols vary. | Research protocols vary. Often studied alongside zinc supplementation. Typical research doses in the microgram range. |
| Administration | Subcutaneous injection once weekly, typically in abdomen, thigh, or upper arm. Rybelsus is taken orally on empty stomach. Dose titration is essential to minimize GI side effects. | Subcutaneous or intramuscular injection in research settings. Requires adequate zinc status for activity. |
| Side Effects | Common: nausea, vomiting, diarrhea, constipation, abdominal pain. These typically decrease over time. May cause injection site reactions. | Limited data on exogenous administration. Theoretical effects on immune function require monitoring. |
| Best For |